Novo Nordisk A/S (NYSE:NVO) Trading 5.1% Higher After Analyst Upgrade

Novo Nordisk A/S (NYSE:NVO) traded up 5.1% on Wednesday after Morgan Stanley upgraded the stock from an underweight rating to an equal weight rating. Morgan Stanley now has a $40.00 price target on the stock. Novo Nordisk A/S traded as high as $38.60 and last traded at $38.53. 26,442,539 shares traded hands during mid-day trading, a decline of 2% from the average session volume of 27,024,658 shares. The stock had previously closed at $36.66.

Several other equities analysts have also recently weighed in on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, HSBC restated a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Five research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $53.93.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley upgraded NVO to Equal‑weight and set a $40 price target, citing that the recent sell‑off has better priced in mid‑term risks — a catalyst for short‑term buying. Morgan Stanley upgrade
• Positive Sentiment: Novo announced significant capacity investments: a $372.5M expansion in Monksland, Athlone (Ireland) and a €432M upgrade to produce oral Wegovy — signals of management backing long‑term growth in obesity/GLP‑1. Monksland expansion Ireland facility upgrade
• Neutral Sentiment: Goldman Sachs reaffirmed a Neutral rating on NVO — supportive of no dramatic re‑rating but not a bullish endorsement. Goldman Sachs reaffirms Neutral
• Negative Sentiment: The U.S. FDA sent Novo a second warning letter ordering it to stop a consumer Ozempic ad, saying the commercial makes false or misleading claims — raises regulatory scrutiny and potential marketing limitations for a core franchise. Reuters: FDA warning
• Negative Sentiment: Industry groups (AHA) are urging HRSA to block Novo’s new claims‑data submission policy affecting 340B hospitals — potential policy & reimbursement friction that could pressure margins or access. AHA on 340B policy
• Negative Sentiment: Investor litigation risk surfaced as Pomerantz LLP opened an investigation into Novo Nordisk investors — a potential headwind if suits follow regulatory or disclosure claims. Pomerantz investor investigation
• Negative Sentiment: Novo said it will halve the U.S. list price of Wegovy in 2027 — direct pricing pressure on a growth driver that may weigh on revenue expectations. Wegovy price cut
• Negative Sentiment: Competitive and generic threats: Aspen expects a Canada nod for a generic Ozempic this year and Roche is publicly targeting share gains in weight‑loss — potential market share and pricing headwinds. Aspen generic Ozempic Roche competition

Institutional Investors Weigh In On Novo Nordisk A/S

A number of institutional investors have recently added to or reduced their stakes in the business. AG Campbell Advisory LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $122,000. Rehmann Capital Advisory Group increased its holdings in Novo Nordisk A/S by 33.6% in the fourth quarter. Rehmann Capital Advisory Group now owns 18,552 shares of the company’s stock valued at $944,000 after purchasing an additional 4,664 shares during the period. SHP Wealth Management bought a new position in Novo Nordisk A/S during the 4th quarter worth $67,000. Bank of Hawaii lifted its holdings in Novo Nordisk A/S by 80.7% during the 4th quarter. Bank of Hawaii now owns 8,345 shares of the company’s stock worth $425,000 after buying an additional 3,727 shares during the period. Finally, Sankala Group LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth about $516,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

The stock has a market cap of $171.95 billion, a P/E ratio of 11.10 and a beta of 0.73. The business has a 50-day simple moving average of $51.96 and a 200 day simple moving average of $52.58. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.